Tanya Siddiqi, MD, medical director of lymphoma, City of Hope, Orange County, California, discusses the primary analysis of the TRANSCEND CLL 004 trial. This phase 1/2, single-arm, multicenter study was designed to evaluate lisocabtagene maraleucel in patients with refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Dr Siddiqi notes that that lisocabtagene maraleucel treatment led to durable complete response and complete response with incomplete marrow recovery, high undetectable minimal residual disease rates, and a manageable safety profile in this heavily pretreated, high-risk population.